TY - JOUR
T1 - Controlled release of doxorubicin from polyethylene glycol functionalized melanin nanoparticles for breast cancer therapy
T2 - Part I. Production and drug release performance of the melanin nanoparticles
AU - Ozlu, Busra
AU - Kabay, Gozde
AU - Bocek, Ilyas
AU - Yilmaz, Merve
AU - Piskin, Ayse Kevser
AU - Shim, Bong Sup
AU - Mutlu, Mehmet
N1 - Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/10/30
Y1 - 2019/10/30
N2 - In this study, polyethylene glycol (PEG) conjugated melanin nanoparticles (MNPs) were prepared (PEG-MNPs). A model chemotherapy drug, doxorubicin (DOX), was loaded into the PEG-MNPs with varied concentrations (0.125, 0.250, 0.500 mg/mL). TEM images showed that, DOX-PEG-MNPs are spherical-shaped and 15 ± 2.2 nm in diameter. FTIR spectroscopy analysis demonstrated that MNPs were successfully modified with PEG. The UV–Vis spectroscopy results showed that the drug loading capacity of MNPs was 0.7 mg/ml of DOX in 2 mg/ml of PEG-MNPs. The time course data showed that, the release behavior of DOX from MNPs was primarily diffusion controlled. In vitro cytotoxicity assays demonstrated that MNP and PEG-MNP did not show any toxic effect on mouse fibroblast cells while DOX-PEG-MNP was able to inhibit the proliferation of human breast cancer cells. The results confirm that the application area of MNPs in controlled and prolonged drug release could be extended to the different types of cancer therapeutics.
AB - In this study, polyethylene glycol (PEG) conjugated melanin nanoparticles (MNPs) were prepared (PEG-MNPs). A model chemotherapy drug, doxorubicin (DOX), was loaded into the PEG-MNPs with varied concentrations (0.125, 0.250, 0.500 mg/mL). TEM images showed that, DOX-PEG-MNPs are spherical-shaped and 15 ± 2.2 nm in diameter. FTIR spectroscopy analysis demonstrated that MNPs were successfully modified with PEG. The UV–Vis spectroscopy results showed that the drug loading capacity of MNPs was 0.7 mg/ml of DOX in 2 mg/ml of PEG-MNPs. The time course data showed that, the release behavior of DOX from MNPs was primarily diffusion controlled. In vitro cytotoxicity assays demonstrated that MNP and PEG-MNP did not show any toxic effect on mouse fibroblast cells while DOX-PEG-MNP was able to inhibit the proliferation of human breast cancer cells. The results confirm that the application area of MNPs in controlled and prolonged drug release could be extended to the different types of cancer therapeutics.
KW - Breast cancer
KW - Controlled release
KW - Doxorubicin
KW - Melanin nanoparticle
KW - Nano-sized drug delivery
UR - http://www.scopus.com/inward/record.url?scp=85072211461&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2019.118613
DO - 10.1016/j.ijpharm.2019.118613
M3 - Article
C2 - 31415880
AN - SCOPUS:85072211461
SN - 0378-5173
VL - 570
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 118613
ER -
